9 months ago
Motilal Oswal Recommends 3 Stocks with 17-30% Upside
Motilal Oswal, a brokerage firm, has recommended three stocks that they believe could offer good returns in the next few years.
The first stock is GAIL, which they think could go up by 25%.
They believe GAIL's stock price has dropped enough to recover, and they expect better gas demand and improved profits.
The second stock is Privi Speciality Chemicals, which they think could go up by 30%.
They expect the company to grow because they are increasing their production and adding new products.
The third stock is Global Health, which runs Medanta hospitals.
They think this stock could go up by 17% because of a new hospital in Noida and other expansion plans.
Overall, these recommendations are based on the companies' growth plans and industry trends.
Motilal Oswal recommends GAIL with a 25% upside potential, targeting Rs 220.
Privi Speciality Chemicals is expected to grow with a 30% upside, targeting Rs 3,960.
Global Health is recommended with a 17% upside, targeting Rs 1,480.
GAIL's growth is driven by increased natural gas transmission and improved profitability.
Privi Speciality Chemicals plans to increase production capacity and diversify products.
- Who
- Motilal Oswal, a brokerage firm
- What
- Recommended three stocks with significant upside potential
- Where
- India, focusing on GAIL, Privi Speciality Chemicals, and Global Health
- When
- Current analysis and future projections
- Why
- Based on growth potential, demand, and industry trends
Key facts
- Stock 1
- GAIL
- Target Price (GAIL)
- Rs 220
- Upside Potential (GAIL)
- 25%
- Stock 2
- Privi Speciality Chemicals
- Target Price (Privi)
- Rs 3,960
- Upside Potential (Privi)
- 30%
- Stock 3
- Global Health
- Target Price (Global Health)
- Rs 1,480
- Upside Potential (Global Health)
- 17%
- Expected CAGR (Privi)
- 27%/34% in revenue/EBITDA over FY25-28
- Capacity Increase (Privi)
- 48,000 to 66,000 tonnes by March 2028
- New Capacity (Privi)
- 18,000 tonnes in FY27, 36,000 tonnes by FY29
- EBITDA Breakeven (Global Health)
- 12-15 months for Noida facility
- Expansion Plans (Global Health)
- Mumbai, South Delhi, Guwahati, Pithampura, and other regions
Quotes
Motilal Oswal
A brokerage firm
“We expect Privi Speciality Chemicals to deliver a CAGR (Compound Annual Growth Rate) of 27%/34% in revenue/EBITDA over FY25-28, driven by an increase in capacity of its core products, an increase in TAM (Total Addressable Market) with the addition of new products, and improving relationships with existing customers (Givaudan).”
financialexpress.com
“an increase in natural gas transmission volumes to 132 mmscmd (million metric standard cubic meters per day) in FY28 from 123 mmscmd in FY26.”
financialexpress.com
Sources
Related news
Sharma and Malik share halfway lead at Telangana Golconda Masters
Films Raise Awareness of Violence but Cannot End It
Teen Allegedly Gangraped on Moving Delhi Bus; Two Arrested
Noida Intensifies Bus Checks After Gang-Rape; Delhi, RTO Absent
NHRC Seeks Police Reports Over Alleged Minor’s Bus Gang Rape
